EPPA
13.1.2023 05:01:38 CET | Business Wire | Press release
The European Paper Packaging Alliance (EPPA) has this week welcomed a new President and Director General.
At EPPA’s General Assembly on 9 January, Antonio D’Amato, CEO of Seda International Packaging Group and former president of Confindustria, the Confederation of Italian Industry, has been elected President. He took over from Eric Le Lay, President of Huhtamaki Fibre Food Service who is now Vice-President of the Alliance.
EPPA also appointed Matti Rantanen, an experienced packaging expert and public affairs professional, as its new Director General.
2023 will be a pivotal year for the European packaging industry as discussions on the EU’s proposed Packaging and Packaging Waste Regulation heat up. The European Commission is proposing the mass implementation of reusable packaging across a range of sectors - in spite of life cycle analysis clearly showing it to be the least sustainable choice. EPPA will be making the case for the best environmental, renewable and recyclable single-use paper packaging.
Incoming EPPA President Antonio D'Amato said:
"I am honoured to take on the Presidency of EPPA again and thank all its members, particularly Eric Le Lay, for their excellent work over the past year. EPPA increasingly represents the leading companies in Europe’s paper packaging supply chain, from forest, paper and board producers to converters and brand owners as well. We will maintain our focus on continuing the innovative, sustainable development of single-use paper packaging that is fully integrated in the circular economy.
Our mission is increasingly focused on supporting policymakers to make decisions based on solid scientific evidence. Single-use paper packaging has an essential role to play in reducing CO2 emissions while simultaneously reducing food waste, avoiding water stress and protecting consumer health."
Eric Le Lay, President of Fiber & Foodservice at Huhtamaki and Vice-President of EPPA said:
“I am delighted to pass on the torch to Antonio D’Amato this year. He brings a wealth of experience to the role. Our biggest challenge is to engage constructively on the complex Packaging and Packaging Waste Regulation file. We will continue to make the case for recyclable, renewable paper-based packaging at the heart of Europe’s circular economy and ensure that policies are based on science and evidence.”
Matti Rantanen, Director General of the European Paper Packaging Alliance added:
“I am excited to join EPPA and work to promote recyclable and renewable paper packaging as a solution to achieve a fully circular economy. Reviewing the EU’s packaging and packaging waste rules is crucial, yet it must be done rationally and in accordance with scientific evidence. EPPA’s studies have shown that in quick-service restaurants, both for in-store consumption and takeaway services, single-use paper packaging is simply better for the environment, the economy and consumer health. I am dedicated to getting this message across. As we continue to feel the effects of climate change and of the global economic crisis everyday, EPPA will continue to offer facts and evidence that should be acknowledged by policy makers.”
ENDS
About EPPA:
The European Paper Packaging Alliance is a non-for-profit food and foodservice packaging association. The priorities of the Alliance are to find concrete solutions to increase recycling and to reduce carbon emissions of food and foodservice packaging without compromising food safety and human health protection. More information is available here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005686/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
